Drug stops spread of cancer in trial patients

Recipients of targeted gene treatment see their tumours shrink or stabilise

A new type of cancer treatment which kills malignant cells but leaves healthy cells unscathed has shown remarkable promise in its first trial.

More than half the 60 patients who received the targeted treatment saw their tumours shrink or stabilise, despite having previously tried other therapies which had failed to curb the progress of their disease. One patient who had advanced cancer is still in remission after two years.

The findings are announced today in the New England Journal of Medicine, which has taken the unusual decision to publish the small trial at such an early stage because of its "important results". An accompanying editorial says they "point to a new direction in the development of anti-cancer drugs".

The announcement comes five days after scientists at the Mayo Clinic in the US reported success with a new drug for prostate cancer. Two patients who had "inoperable" tumours were treated with the drug ipilimumab, a monoclonal antibody that stimulates the immune system. After one infusion, their tumours shrank enough to be surgically removed and both men have made a full recovery.

The latest development involves a different drug, olaparib, which works in a different way by targeting the genetic defect that causes cells to turn cancerous. In a process called "synthetic lethality", the drug has been engineered to chemically inhibit one type of gene, which then acts with the abnormal cancer gene to kill cancer cells in which both are present.

Initial tests have been carried out in patients with inherited breast, ovarian and prostate cancer caused by mutations in the BRCA1 and BRCA2 genes. People with these genetic mutations – about one in 500 people – have a high risk of developing cancer, of up to 80 per cent in the case of breast cancer.

Johann de Bono, a scientist at the Institute of Cancer Research and the leader of the study conducted in the UK and the Netherlands, said the trial showed "very impressive results".

"It's giving patients who have already tried many conventional treatments long periods of remission, free from the symptoms of cancer or major side effects." Professor Stan Kaye, the joint lead researcher from the institute, said: "This is a very important drug for the the treatment of BRCA1/2-related cancer. The next step is to test the drug on other more common types of ovarian and breast cancers where we hope it will be just as effective."

Julian Lewis, 62, who was diagnosed in 2004 with prostate cancer which had spread to his bones, has been on olaparib for two years. The drug has held his prostate cancer in check and the cancer in his bones "seems almost to have disappeared", he said.

Married with three daughters, he lives in Oxford and works as a cancer researcher himself. He is a BRCA2 mutation carrier and his sister died of ovarian cancer.

"It has always been the dream of cancer research to discover drugs that will kill the cancer cells while leaving healthy cells unharmed," he said.

"Now we have the tools in terms of genes to discover what has gone wrong in the cells of a cancer to make them misbehave. If you can pinpoint the key mutation that makes them dangerously different, you can use that to kill the cells selectively. In other words you can turn the weapon of the mischief-maker against the mischief-maker itself."

The drug is now being tested in further larger trials across the world.

PROMOTED VIDEO
Life and Style
ebookNow available in paperback
ebooks
ebookPart of The Independent’s new eBook series The Great Composers
Arts and Entertainment
Frank Turner performing at 93 Feet East
musicReview: 93 Feet East, London
News
Toronto tops the charts across a range of indexes
news

World cities ranked in terms of safety, food security and 'liveability'

Extras
indybest
Voices
A mother and her child
voices
Voices
The veterans Mark Hayward, Hugh Thompson and Sean Staines (back) with Grayson Perry (front left) and Evgeny Lebedev
charity appealMaverick artist Grayson Perry backs our campaign
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Recruitment Genius: Project Coordinator

    Negotiable: Recruitment Genius: Due to expansion this leading designer and sup...

    Recruitment Genius: Recruitment Assistant

    £19000 - £21000 per annum: Recruitment Genius: Are you a friendly, confident i...

    Tradewind Recruitment: Primary Teaching Assistant

    Negotiable: Tradewind Recruitment: At Tradewind Recruitment we are currently l...

    Tradewind Recruitment: Physics Teacher

    Negotiable: Tradewind Recruitment: Tradewind Recruitment is currently working ...

    Day In a Page

    Isis hostage crisis: The prisoner swap has only one purpose for the militants - recognition its Islamic State exists and that foreign nations acknowledge its power

    Isis hostage crisis

    The prisoner swap has only one purpose for the militants - recognition its Islamic State exists and that foreign nations acknowledge its power, says Robert Fisk
    Missing salvage expert who found $50m of sunken treasure before disappearing, tracked down at last

    The runaway buccaneers and the ship full of gold

    Salvage expert Tommy Thompson found sunken treasure worth millions. Then he vanished... until now
    Homeless Veterans appeal: ‘If you’re hard on the world you are hard on yourself’

    Homeless Veterans appeal: ‘If you’re hard on the world you are hard on yourself’

    Maverick artist Grayson Perry backs our campaign
    Assisted Dying Bill: I want to be able to decide about my own death - I want to have control of my life

    Assisted Dying Bill: 'I want control of my life'

    This week the Assisted Dying Bill is debated in the Lords. Virginia Ironside, who has already made plans for her own self-deliverance, argues that it's time we allowed people a humane, compassionate death
    Move over, kale - cabbage is the new rising star

    Cabbage is king again

    Sophie Morris banishes thoughts of soggy school dinners and turns over a new leaf
    11 best winter skin treats

    Give your moisturiser a helping hand: 11 best winter skin treats

    Get an extra boost of nourishment from one of these hard-working products
    Paul Scholes column: The more Jose Mourinho attempts to influence match officials, the more they are likely to ignore him

    Paul Scholes column

    The more Jose Mourinho attempts to influence match officials, the more they are likely to ignore him
    Frank Warren column: No cigar, but pots of money: here come the Cubans

    Frank Warren's Ringside

    No cigar, but pots of money: here come the Cubans
    Isis hostage crisis: Militant group stands strong as its numerous enemies fail to find a common plan to defeat it

    Isis stands strong as its numerous enemies fail to find a common plan to defeat it

    The jihadis are being squeezed militarily and economically, but there is no sign of an implosion, says Patrick Cockburn
    Virtual reality thrusts viewers into the frontline of global events - and puts film-goers at the heart of the action

    Virtual reality: Seeing is believing

    Virtual reality thrusts viewers into the frontline of global events - and puts film-goers at the heart of the action
    Homeless Veterans appeal: MP says Coalition ‘not doing enough’

    Homeless Veterans appeal

    MP says Coalition ‘not doing enough’ to help
    Larry David, Steve Coogan and other comedians share stories of depression in new documentary

    Comedians share stories of depression

    The director of the new documentary, Kevin Pollak, tells Jessica Barrett how he got them to talk
    Has The Archers lost the plot with it's spicy storylines?

    Has The Archers lost the plot?

    A growing number of listeners are voicing their discontent over the rural soap's spicy storylines; so loudly that even the BBC's director-general seems worried, says Simon Kelner
    English Heritage adds 14 post-war office buildings to its protected lists

    14 office buildings added to protected lists

    Christopher Beanland explores the underrated appeal of these palaces of pen-pushing
    Human skull discovery in Israel proves humans lived side-by-side with Neanderthals

    Human skull discovery in Israel proves humans lived side-by-side with Neanderthals

    Scientists unearthed the cranial fragments from Manot Cave in West Galilee